Analysis of contaminants in factor VIII preparations administered to patients with hemophilia.
Cryoprecipitate and the more purified factor VIII concentrates are all heterogeneous preparations that contain not only a high concentration of factor VIII but also various other materials, some of which might be injurious, causing liver damage after long-term exposure. The efficiency of three standard cryoprecipitate filters, two microaggregate filters and the appropriate factor VIII concentrate filters in reducing the amount of particulate matter delivered to the patient was assessed. Filtration of cryoprecipitate through the standard filters removed less than 20% of the contaminating microaggregates and very few of the large number of intact platelets, although the total dose of factor VIII was delivered. Microaggregate filters were no better in reducing the platelet contamination, although the total number of particles delivered was halved. However, 25% of the factor VIII was retained in the bed volume of the filter. The concentrate preparations also contained significant amounts of particulate matter that was unrelated to factor VIII and was not removed following filtration through the designated filter. These findings indicate that a new filter should be developed for administration of factor VIII concentrate that would remove the particulate matter while delivering all of the factor VIII to the patient.
D004051:Diethylhexyl Phthalate / Q000031:analogs & derivatives / Q000032:analysis; D004591:Electrophoresis, Polyacrylamide Gel; D005169:Factor VIII / Q000302:isolation & purification* / Q000627:therapeutic use; D005374:Filtration; D006467:Hemophilia A / Q000628:therapy*; D006801:Humans; D008854:Microscopy, Electron
D005169:Factor VIII; D004051:Diethylhexyl Phthalate; C016599:mono-(2-ethylhexyl)phthalate